Latest News

  • 13th August 2026

    Peer-Reviewed Publication of AT278 Study in Diabetes, Obesity and Metabolism journal

  • 3rd August 2026

    Clarivate report – Companies to Watch 2026: Seven innovators shaping next-generation obesity therapies

  • 30th July 2026

    Diabetes, Obesity and Metabolism article – A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI

News

For regulatory news click here

Reset
  • 13/08/2026

    Peer-Reviewed Publication of AT278 Study in Diabetes, Obesity and Metabolism journal

  • 30/07/2026

    Diabetes, Obesity and Metabolism article – A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI

  • 03/08/2026

    Clarivate report – Companies to Watch 2026: Seven innovators shaping next-generation obesity therapies

  • 18/05/2026

    Upcoming conference attendance

  • 28/04/2026

    BioSpace podcast – The next era of diabetes management

  • 09/03/2026

    Arecor to present at Oppenheimer Annual Healthcare MedTech & Services Conference (16 March 2026)

  • 23/02/2026

    Arecor talks to Biotech TV

  • 07/01/2026

    Arecor and Sequel Med Tech Fireside Panel Discussion